Grifois (GRFS) Stock: Buy, Sell, or Hold?
GRFS - Grifois, S.A.
$7.31
0.01 (0.14%)
▲
5d:
-0.54%
30d:
-6.64%
90d:
+1.95%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Sep 28, 2026
0d
Get Alerted When GRFS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GRFS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GRFS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$16.06
Based on 14.2% avg growth
INTRINSIC VALUE TODAY
$9.97
26.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GRFS is currently trading at $7.31, which is considered slightly low relative to its 30-day fair value range of $7.30 to $7.79. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.1) compared to its historical average (5.8). Remarkably, the market is currently pricing in an annual earnings decline of 4.4% over the next few years. This pessimistic expectation contrasts with the company's recent 32.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GRFS is showing sideways momentum. The price is currently testing key support at $7.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GRFS scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.87 (+48.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GRFS is showing sideways momentum. The price is currently testing key support at $7.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GRFS scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.87 (+48.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$7.30 -
$7.79
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (84/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 48.6% below Wall St target ($10.87)
- CAUTION: Bottoming setup, but lagging the sector by 21% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$7.30 -
$7.79
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$7.15
Resistance Level
$7.47
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.07
Wall Street Target
$10.87
(+48.6%)
Revenue Growth (YoY)
-0.9%
Earnings Growth (YoY)
32.9%
Profit Margin
6.1%
Valuation Discount vs History
-4.4% cheaper
PE vs Historical
5.1 vs 5.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.4%
(market-implied from PE analysis)
1-Year Target
$6.99
(-4%)
2-Year Target
$6.68
(-9%)
3-Year Target
$6.39
(-13%)
3-Yr Target (if PE normalizes)
(PE: 5→6)
$7.31
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 24.3%)
$56.50
(+673%)
Base:
(SPY PE: 5.1, Growth: 24.3%)
$14.04
(+92%)
Bear:
(PE: 4.3, Growth: 24.3%)
$11.93
(+63%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (10x PE), but valuation improves significantly next year (5x PE) as earnings recover.
Trailing PE: 9.73 | Current EPS (TTM): $0.75
Bull Case
$15.44
(+111%)
Analyst growth 92.3%, PE expands to 10.7
Base Case
$14.04
(+92%)
Market implied 92.3%, PE stable at 9.7
Bear Case
$4.96
(-32%)
Severe decline -20.0%, PE contracts to 8.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.1 to 5.8
Stabilization Target:
$8.37
(+14.5%)
PE Expansion Potential:
+14.5%
Share & Embed Analysis
Last updated: October 03, 2026 1:11 PM ET
Data refreshes hourly during market hours. Next update: 2:11 PM
Data refreshes hourly during market hours. Next update: 2:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRFS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1325 | 48 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$159 | 46 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$279 | 57 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$389 | 55 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$238 | 48 HOLD |
